Mode
Text Size
Log in / Sign up

In an RCT, dutasteride significantly reduced total International Prostate Symptom Score in men with lower urinary tract symptoms over 24 monthsDutasteride Helps Bladder Flow, But Nighttime Relief Takes Years

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider dutasteride for LUTS; significantly improved total IPSS and voiding at 24 months, but safety data not reported.

This randomized controlled trial evaluated the efficacy of dutasteride versus placebo in men with lower urinary tract symptoms. The study included a sample size of 8122 participants and maintained a follow-up duration of 24.0 months. The primary outcome assessed was the International Prostate Symptom Score and its subscores.

At the 24-month mark, dutasteride resulted in a significantly reduced total International Prostate Symptom Score compared to placebo, with a p-value of < 0.001. Similarly, the voiding subscore was significantly reduced (p < 0.001). However, storage symptoms showed no significant reduction (p = 0.09), and nocturia was not significantly reduced (p = 0.2) at this time point.

Longer-term analysis at 4 years indicated improvement in storage symptoms by 0.62 points (p < 0.001) and improvement in nocturia (p = 0.003). The study did not report adverse events, serious adverse events, discontinuations, or tolerability data. No limitations were explicitly listed in the provided data, and funding or conflicts of interest were not reported.

The practice relevance suggests that timely, comprehensive management of lower urinary tract symptoms may require additional therapy. Clinicians should interpret these findings with caution given the lack of reported safety data and the specific timing of symptom improvements.

Waking up three times a night is exhausting. You try to sleep, but your bladder says otherwise. This routine drains your energy and ruins your mood.

Many men face these issues as they age. It affects sleep and mood. It also makes daily tasks harder to manage.

Doctors often prescribe drugs to help men pee better. These medicines target the prostate gland directly. But not all symptoms get fixed at the same speed.

Some men feel relief right away. Others wait months or years for results. This delay causes frustration for patients and families.

The surprising shift

We used to believe one drug fixed everything. New data shows a delay in how it works. The timing changes what you can expect.

Doctors now know flow improves fast. But storage issues take much longer to change. This distinction is vital for managing expectations.

How the drug acts

Think of the prostate like a valve on a hose. It squeezes the tube when it gets too big. The drug shrinks the valve to open the path.

This helps urine move out faster. It does not always stop the urge to go. The body needs time to adjust to the change.

Researchers reviewed 8122 men in this large review. They were tracked for four years of treatment. The group included both placebo and drug users.

Men taking the drug saw better flow at two years. Their total symptom scores dropped significantly. This was a clear win for emptying the bladder.

But storage symptoms did not improve until year four. The change was statistically real but small. It was a 0.62 point improvement on a scale.

This is where the story gets complicated.

Experts say one drug might not be enough. Many men need a combination of therapies. A single pill rarely solves every problem.

What to do next

Talk to your doctor about your specific goals. Ask if the delay fits your lifestyle. You might need extra help for night trips.

Do not stop taking your medication without advice. The drug still helps with flow and safety. Just know the full picture of benefits.

The hidden limitation

The improvement was modest and unlikely to be meaningful. It might not feel different in real life. Small numbers do not always equal big relief.

Some men might not notice the change at all. This is why comprehensive management is key. You may need more than just one tool.

More studies will look for better solutions. Researchers want to find faster ways to help. Approval timelines depend on these future trials.

Patience is required for new medical advances. Science moves slowly to ensure safety. We wait for better options to arrive.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up24.0 mo
PublishedDec 2026
View Original Abstract ↓
BACKGROUND: Dutasteride is used to treat voiding symptoms; its impact on storage symptoms is unclear. METHODS: We reviewed 8122 men in the placebo and dutasteride arms from the REDUCE trial. Lower urinary tract symptoms outcomes were measured with international prostate symptom score and subscores. RESULTS: At 2-year follow-up, dutasteride significantly reduced the total International Prostate Symptom Score and voiding subscore versus placebo (both < 0.001), but not storage symptoms (= 0.09) or nocturia (= 0.2). By 4 years, improvements in the total score and voiding subscores remained, but now extended to storage symptoms (< 0.001) and nocturia (= 0.003), though the impact on storage symptoms was modest (0.62 points improvement). CONCLUSION: While dutasteride reduces storage symptoms, it takes several years, and the overall effect is modest and unlikely to be clinically meaningful. Timely, comprehensive lower urinary tract symptoms management may require additional therapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.